Description:

Terifrac is a medication manufactured by Intas Pharmaceuticals Ltd. It contains the active ingredient Teriparatide, which is a synthetic form of parathyroid hormone (PTH). Teriparatide is primarily used in the treatment of osteoporosis, a condition characterized by weakened bones and an increased risk of fractures.

Mechanism of Action:

Teriparatide works by stimulating bone formation and increasing bone density. It acts as an anabolic agent, promoting the activity of osteoblasts (cells responsible for bone formation) while inhibiting bone resorption. By increasing bone formation, Teriparatide helps to strengthen bones and reduce the risk of fractures.

Indications:

Terifrac (Teriparatide 750 mcg Injection) is indicated for the treatment of:

• Osteoporosis in postmenopausal women: It is used to reduce the risk of fractures, including vertebral and non-vertebral fractures.
• Osteoporosis in men: Teriparatide is also indicated for the treatment of osteoporosis in men at increased risk of fracture.

Benefits:

• Increased Bone Density: Terifrac stimulates bone formation, leading to an increase in bone density. This helps to strengthen bones and reduce the risk of fractures, particularly in individuals with osteoporosis.
• Reduced Fracture Risk: By promoting bone formation and improving bone quality, Terifrac helps to decrease the risk of fractures, including vertebral and non-vertebral fractures. This is particularly beneficial for postmenopausal women and men with osteoporosis who are at an increased risk of fractures.
• Improved Quality of Life: Treatment with Terifrac can improve the quality of life for individuals with osteoporosis by reducing the risk of fractures and associated complications. This can lead to greater mobility, independence, and overall well-being.
• Potential for Bone Healing: Terifrac may also have potential benefits for bone healing in individuals with osteoporotic fractures or other bone injuries, although further research is needed to fully elucidate its role in this regard.

Dosage and Administration:

• The recommended dosage of Terifrac is 750 mcg (micrograms) administered once daily by subcutaneous injection.
• The injection should be given into the thigh or abdominal wall, as directed by the healthcare provider.
• It is important to follow the instructions provided by the healthcare provider or pharmacist for proper administration of the medication.

Precautions:

• Terifrac should be used with caution in individuals with certain medical conditions, such as hypercalcemia, hyperparathyroidism, or Paget’s disease of the bone.
• It is important to inform the healthcare provider of any pre-existing medical conditions or medications being taken, as they may interact with Teriparatide.
• Terifrac should not be used in pregnant or breastfeeding women unless the potential benefits outweigh the risks.

Note:

Terifrac (Teriparatide 750 mcg Injection) is an important medication in the management of osteoporosis. Its use should be under the supervision of a qualified healthcare professional, and patients are advised to follow their healthcare provider’s recommendations closely for optimal safety and efficacy.